Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

LL-37

Cathelicidin, hCAP-18, FALL-39, CAP-18

Quick Stats
Studies 2230
Trials 95
Score 1
2017 pubmed 11 citations

Cathelicidin (LL-37) and its correlation with pro-oxidant, antioxidant balance and disease activity in systemic lupus erythematosus: a cross-sectional human study.

Sahebari. M M; Roshandel. G G; Saadati. N N; Saghafi. M M; Abdolahi. N N; Rezaieyazdi. Z Z

Key Findings

  • Overall LL‑37 levels are similar between lupus patients and healthy controls
  • In active lupus patients, higher LL‑37 levels are associated with higher disease activity scores
  • LL‑37 levels positively correlate with antioxidant balance (PAB) in lupus patients

Practical Outcomes

  • For the biohacker community, this research doesn’t provide a direct, actionable protocol for using LL‑37 to boost longevity or performance. It suggests LL‑37 is more of a disease‑specific marker rather than a general health supplement, and any attempts to modulate it should be approached with caution and likely limited to clinical settings.

Summary

The study found that the antimicrobial peptide LL‑37 isn’t higher in people with lupus compared to healthy folks, but in those with active disease it goes up as the disease gets worse and it’s linked to the body’s antioxidant balance. This doesn’t give a clear way to use LL‑37 for health hacks in people without lupus.

Abstract

Background Cathelicidin (LL-37), an endogenous antimicrobial peptide, has recently been involved in the pathogenesis of autoimmune diseases. To assess whether LL-37 reflects disease activity, we measured serum levels of it in systemic lupus erythematosus (SLE) patients with active and inactive disease compared to healthy controls. LL-37 was also compared between new and old cases. Moreover, the correlation of LL-37 and pro-oxidant, antioxidant balance (PAB) was measured. Methods The study population consisted of 50 SLE patients and 28 healthy controls. Of those, 39 patients had active and 11 patients had inactive disease. Serum levels of LL-37 were measured by ELISA and PAB values by a special method. Results There was no difference in levels of LL-37 between patients and healthy controls (50.9 ± 20.8 vs. 67.7 ± 43.3 ng/ml, P = 0.31). LL-37 did not correlate with SLEDAI and its items in total patients. LL-37 had a positive correlation with SLEDAI in active patients ( P = 0.01, r = 0.4). In active patients (78% of patients), multivariate regression analysis showed significant negative correlation between LL-37 and C3 ( P = 0.01, standardized beta -0.50). No difference was found in levels of PAB between patients and controls (90.4 ± 34.1 vs. 86.9 ± 25.6 HK, P = 0.4).There was no difference in the levels of PAB between patients with active and inactive disease (93.2 ± 34.1 vs. 80.2 ± 33.7 HK, P = 0.27). No correlation was found between levels of PAB and SLEDAI items and total score. However, a positive correlation between the levels of LL-37 and PAB in SLE patients was found ( r = 0.3, P < 0.01). Conclusion Based on this study, serum LL-37 and PAB did not increase in lupus compared with healthy individuals. LL-37 serum values rose in parallel with SLEDAI in active disease. Positive correlation between serum PAB and LL-37 could be a great achievement of this study that may suggest the role of antioxidants in controlling NETosis.

Study Information

Provider

pubmed

Year

2017

Date

2017-03-17T00:00:00.000Z

DOI

10.1177/0961203317691368

Citations

11

References

19